Tag: Boston Scientific

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to first-line oral anticoagulants (OAC) – including direct oral anticoagulants (DOAC) and warfarin – for stroke risk reduction in patients with […]

Boston Scientific Receives U.S. FDA Approval for The VICI VENOUS STENT™ System

MARLBOROUGH, Mass., May 6, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked […]

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System. Delivered via a minimally-invasive procedure, this transcatheter aortic valve replacement (TAVR) technology is approved for patients with severe aortic stenosis who are considered at […]

Boston Scientific Announces Results For First Quarter 2019

MARLBOROUGH, Mass., April 24, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an operational1 basis and 6.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP […]

Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in Europe. Patients with AF are five times more likely to suffer a stroke than someone with a normal heart […]

Boston Scientific Announces Scheduled Data at EHRA 2019 Congress

MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March 17-19. Two late-breaking clinical trials will be presented, including: Outcomes from AF-FICIENT I, a prospective, multicenter, single arm […]

Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes

MARLBOROUGH, Mass., Feb. 25, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750% notes due 2026, $850 million of 4.000% notes due 2029, $750 millionof 4.550% notes due 2039 and $1.0 billion of 4.700% notes due […]

Boston Scientific Announces Results For Fourth Quarter And Full Year 2018

MARLBOROUGH, Mass., Feb. 6, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an operational1 basis and 7.0 percent on an organic2 basis, all compared to the prior year period. The company reported […]

VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages

LEIPZIG, Germany and MARLBOROUGH, Mass., Jan. 22, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions. Primary safety and efficacy results from the VIRTUS trial […]

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

MARLBOROUGH, Mass. and IRVINE, Calif., Jan. 15, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE:  BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world. All pending cases or appeals in courts and patent offices between […]